Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9880469dc8f12dad7c3ad95c6ab31fe |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 |
filingDate |
2018-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71c392149389e3277ee818d62289777b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3c80d5db109aae8fa9e357cae94e2ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e3f68430b77867ef81f60575d39e6f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db01cb77df54c2a492bbe304e503765f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59d6be7d3db8dc4491cc6a3c450c7d47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60fabfa92135dbf36b4e03c8d4910c6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01a322d2d031c7150d4befc55058c316 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ee98a6553839501c39bb9834ae56bb8 |
publicationDate |
2020-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3687525-A1 |
titleOfInvention |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
abstract |
The present invention relates to the combination therapy of a chemokine receptor 2 (CCR2) antagonist and a PD-1 and / or PD-L1 inhibitor in the treatment of cancer. |
priorityDate |
2017-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |